文献速递湿疹皮炎与荨麻疹

特应性皮炎中的T细胞抑制剂

T-cell inhibitors for atopic dermatitis.
PubMed 文献 · J Am Acad Dermatol · 2017-12-15

本文综述了靶向特应性皮炎炎症通路的新型生物制剂。度普利尤单抗阻断IL-4受体已证明有效;胸腺基质淋巴细胞生成素单抗(AMG157/MEDI9929)和OX40阻断抗体(GBR 830)作用于同一通路更上游。GBR 830在2a期研究中使23例中17例EASI评分降低至少50%,但研究未充分把握检测与安慰剂的统计学差异,尚无3期试验证实疗效。

要点

  • 度普利尤单抗阻断IL-4受体治疗特应性皮炎已证明有效。
  • GBR 830在2a期研究中23例中17例EASI降低≥50%,但未达统计学差异。
  • AMG157/MEDI9929有早期证据减弱过敏原诱导的哮喘反应,但无特应性皮炎公开数据。

核心结论

  • T细胞抑制剂类新药有潜力改善重度特应性皮炎管理,但尚未完成关键临床试验证实疗效。

研究设计与样本

  • 本文为综述,汇总靶向特应性皮炎炎症通路的新型生物制剂临床数据。
  • 提及GBR 830的2a期研究,纳入23例患者。

主要发现

  • GBR 830在2a期研究中使23例中17例EASI评分降低至少50%。
  • 该2a期研究未充分把握检测GBR 830与安慰剂间的统计学差异。
  • AMG157/MEDI9929有早期证据减弱多数过敏原诱导的哮喘反应指标。
  • AMG157/MEDI9929无治疗特应性皮炎的公开数据。

关键数值与推荐

  • GBR 830:2a期研究中23例中17例EASI评分降低至少50%。
  • 度普利尤单抗:已证明作用于IL-4受体治疗特应性皮炎有效。
  • 尚无3期临床试验评估这些T细胞抑制剂的疗效。

临床怎么用

  • 度普利尤单抗可作为靶向IL-4受体的治疗选择。
  • GBR 830和AMG157/MEDI9929尚处于研究阶段,不宜常规临床使用。

局限性

  • GBR 830的2a期研究未充分把握检测与安慰剂的统计学差异。
  • AMG157/MEDI9929无治疗特应性皮炎的公开数据。
  • 尚无3期临床试验评估这些药物的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of atopic dermatitis is changing with the development of novel biologic agents to target specific molecules in the inflammatory cascade. Following the ability of dupilumab has proved its ability to act on the interleukin 4 receptor in treating atopic dermatitis. Thymic stromal lymphopoietin monoclonal antibody (AMG157/MEDI9929) and OX40 blocking antibody (GBR 830) were developed by targeting the same pathway as dupilumab further upstream. The clinical data on the efficacy for these drugs are not yet known. There is some early evidence that AMG157/MEDI9929 attenuates most measures of allergen-induced asthmatic responses. However, there are no public data on its ability to treat atopic dermatitis. In a phase 2a study, GBR 830 showed at least a 50% reduction in the Eczema Area and Severity Index scores of 17 of 23 patients, but it was not sufficiently powered for identification of statistical differences between GBR 830 versus placebo. Although there is potential for these 2 drugs to greatly improve the management of severe atopic dermatitis, significant clinical trials have not yet been completed to prove efficacy, and there are not yet any available phase 3 clinical trials, which are needed to truly evaluate their efficacy in affecting T-cells.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Tidwell WJ, Fowler JF. T-cell inhibitors for atopic dermatitis. J Am Acad Dermatol. 2017. PMID: 29248519. doi:10.1016/j.jaad.2017.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。